Needham & Company LLC Issues Positive Forecast for CryoPort (NASDAQ:CYRX) Stock Price

CryoPort (NASDAQ:CYRX) had its price target raised by Needham & Company LLC from $15.00 to $19.00 in a research note issued to investors on Friday, MarketBeat Ratings reports. The brokerage currently has a buy rating on the stock.

A number of other research analysts have also weighed in on CYRX. KeyCorp raised their price objective on CryoPort from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Jefferies Financial Group set a $13.50 price target on CryoPort in a report on Monday, June 8th. Roth Capital reaffirmed a “buy” rating and set a $21.00 price objective on shares of CryoPort in a report on Friday. Guggenheim raised their target price on shares of CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of CryoPort in a research report on Monday. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

CryoPort Stock Up 2.8%

NASDAQ:CYRX opened at $15.12 on Friday. The business’s 50-day simple moving average is $15.49 and its two-hundred day simple moving average is $11.92. CryoPort has a 52 week low of $7.51 and a 52 week high of $16.89. The stock has a market cap of $762.05 million, a PE ratio of -16.80 and a beta of 1.89.

CryoPort (NASDAQ:CYRX) last issued its earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The company had revenue of $48.97 million for the quarter, compared to the consensus estimate of $48.18 million. CryoPort had a negative return on equity of 7.13% and a negative net margin of 20.05%. Sell-side analysts anticipate that CryoPort will post -0.85 earnings per share for the current fiscal year.

Insider Buying and Selling at CryoPort

In other CryoPort news, insider Edward J. Zecchini sold 33,600 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $14.47, for a total transaction of $486,192.00. Following the sale, the insider directly owned 109,719 shares in the company, valued at $1,587,633.93. This represents a 23.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Ramkumar Mandalam sold 23,214 shares of CryoPort stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $15.44, for a total value of $358,424.16. Following the completion of the transaction, the director owned 67,894 shares of the company’s stock, valued at approximately $1,048,283.36. This trade represents a 25.48% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 227,641 shares of company stock worth $3,622,515 over the last ninety days. Company insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CYRX. Basepoint Wealth LLC purchased a new stake in shares of CryoPort in the fourth quarter valued at $34,000. Tower Research Capital LLC TRC grew its holdings in CryoPort by 300.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock valued at $44,000 after purchasing an additional 4,375 shares during the last quarter. Quadrature Capital Ltd purchased a new stake in CryoPort in the 4th quarter worth about $97,000. Corient Private Wealth LLC purchased a new stake in CryoPort in the 4th quarter worth about $113,000. Finally, BNP Paribas Financial Markets lifted its stake in CryoPort by 55.2% in the third quarter. BNP Paribas Financial Markets now owns 11,880 shares of the company’s stock worth $113,000 after purchasing an additional 4,225 shares during the last quarter. 92.90% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about CryoPort

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Needham raised its price target to $19 from $15 and reiterated a “buy” rating, implying substantial upside from recent trading levels. The upgrade reflects confidence in CryoPort’s growth outlook and pipeline exposure. Benzinga report
• Positive Sentiment: Second-quarter revenue increased 8% year over year to approximately $49.0 million. Life Sciences Services revenue rose 15%, while BioStorage/BioServices revenue grew 25%, showing accelerating demand in key businesses. CryoPort was supporting 779 clinical trials and 22 commercially approved cell and gene therapies at quarter-end. CryoPort second-quarter results
• Positive Sentiment: Investor confidence has improved alongside CryoPort’s expanding pipeline. Conestoga Capital Advisors highlighted the company in its second-quarter investor letter, providing additional institutional-investor support for the growth story. Investor confidence report
• Neutral Sentiment: Management’s fiscal 2026 revenue guidance of $192 million to $196 million brackets the analyst consensus of $194.2 million, signaling continued growth but no major near-term guidance surprise. Q2 2026 earnings call transcript
• Negative Sentiment: Adjusted quarterly EPS was a loss of $0.20, narrowly below the $0.19 loss expected by analysts. Although the loss improved from $0.29 per share a year earlier, the slight earnings miss and CryoPort’s negative return on equity remain concerns for investors. CryoPort Q2 earnings report

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.